Clinical Trial Detail

NCT ID NCT01727089
Title Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

kidney cancer

Therapies

Bevacizumab

Bevacizumab + Carotuximab

Age Groups: adult

No variant requirements are available.